Thursday 12 Jun, 2025 04:58 AM
Site map | Locate Us | Login
   HCL Tech rallies on expanding partnership with The Standard    Indian Energy Exchange Ltd leads losers in 'A' group    Harsha Engineers International Ltd leads losers in 'B' group    India Ratings downgrades ratings of Spandana Sphoorty to 'A-' with 'negative' outlook    Volumes soar at Tata Teleservices (Maharashtra) Ltd counter    Minda Corporation edges higher after signing JV pact with Japanese firm Toyodenso    Divis Laboratories Ltd up for third consecutive session    Natco Pharma Ltd gains for third consecutive session    Biocon Ltd soars 3.52%, Gains for third straight session    Lloyds Metals & Energy Ltd spurts 1.13%, rises for third straight session    Hathway Cable & Datacom Ltd gains for third straight session    Zee Entertainment Enterprises Ltd up for third straight session    Cipla Ltd spurts 0.42%, up for fifth straight session    Glenmark Pharmaceuticals Ltd soars 0.98%, rises for fifth straight session    NMDC Ltd spurts 0.54%, gains for fifth straight session 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
AstraZeneca Pharma slides as MD Sanjeev Panchal steps down; Praveen Rao Akkinepally to take charge
10-Jun-25   09:49 Hrs IST

Panchal is set to transition to a global role within the AstraZeneca Group, based in Gaithersburg, Maryland, US. The board acknowledged his resignation and placed on record its appreciation for his contributions during his tenure.

Following the recommendation of the nomination and remuneration committee, the board has approved the appointment of Praveen Rao Akkinepally as the new MD. He will take charge from 1 July 2025, for a term of three years.

Akkinepally is a senior commercial leader with over two decades of experience across the US, global markets, and India, particularly in oncology and biopharmaceuticals. He has led several brand launches and driven global commercial strategies at AstraZeneca.

His previous role as oncology business unit head for India saw significant growth in the company's market presence and a series of successful oncology product launches.

Beyond his corporate achievements, he has contributed to healthcare policy through his work with the Federation of Indian Chambers of Commerce and Industry's cancer round tables.

Akkinepally holds an MBA from the University of Michigan's Ross School of Business and a master's in public health from Johns Hopkins University.

AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in four areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Rare Diseases. It operates in over 100 countries.

The company's standalone net profit rose 47.54% to Rs 58.25 crore, while revenue from operations rose 25.39% to Rs 480.48 crore in Q4 March 2025 over Q4 March 2024.

Powered by Capital Market - Live News

   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Hit Count : 41867407
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL Securities Private Limited